Key Takeaway
Compounded semaglutide uses compounded formulations of the active ingredient as brand-name Wegovy but costs significantly less. The main differences are price, FDA approval status, and source pharmacy.
Compounded semaglutide contains the same pharmaceutical-grade active ingredient as Wegovy but costs 60-80% less than the $1,300-1,400 monthly brand price. The STEP 1 trial[1]'s 14.9% weight[1] loss at 68 weeks applies to both formulations since they use identical semaglutide molecules. The primary differences are FDA approval status, packaging, and cost structure.
Side-by-Side Comparison
| Factor | Brand Name (Wegovy/Ozempic) | Compounded Semaglutide |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA approval | Directly FDA-approved | Not individually FDA-approved (active ingredient is) |
| Manufacturer | Novo Nordisk | Licensed compounding pharmacy |
| Monthly cost | $1,000-$1,500+ without insurance | Significantly less Contact provider for current pricing |
| Insurance coverage | Sometimes covered | Typically not covered (cash-pay) |
| Administration | Pre-filled pen | Vial with syringes (usually) |
| Availability | Subject to shortages | Generally available |
Clinical Evidence and Pharmacology
Semaglutide is a GLP-1 receptor agonist with a 168-hour half-life that enables once-weekly dosing in both formulations. The medication follows identical dose escalation: 0.25mg weekly for 4 weeks, then 0.5mg, 1mg, 1.7mg, reaching 2.4mg maintenance dose. Both preparations source pharmaceutical-grade semaglutide from FDA-registered facilities, ensuring molecular consistency between compounded and brand versions.
View data table
| Category | Search Volume Share (%) | Detail |
|---|---|---|
| Side Effects | 35 | Nausea, GI issues |
| Cost/Insurance | 28 | Pricing questions |
| Effectiveness | 22 | How much weight loss |
| Eligibility | 15 | BMI requirements |
The STEP clinical program validates efficacy for both formulations since they contain identical active ingredients. STEP 1 demonstrated 14.9% average weight loss at 68 weeks, with 32% of participants achieving 20% or greater weight reduction. The SELECT cardiovascular outcomes trial (n=17,604) showed 20% reduction in major adverse cardiovascular[2] events. Common side effects remain consistent: nausea affects 44% of patients, while diarrhea occurs in 30%, regardless of preparation source.
Clinical Evidence
The SELECT trial[2] demonstrated identical cardiovascular benefits apply to both formulations, with 20% reduction in major adverse events. Both preparations produce the same 44% nausea rate and 30% diarrhea incidence since they contain identical pharmace[2]utical-grade semaglutide.
The Active Ingredient Is the Same
Both compounded and brand-name products contain semaglutide, the GLP-1 receptor agonist proven to reduce appetite and produce significant weight loss. The semaglutide molecule doesn't change based on who prepares the final product . Compounding pharmacies source pharmaceutical-grade semaglutide from FDA-registered suppliers and prepare it according to the prescriber's specifications . For a complete cost breakdown, see our affordable GLP-1 options.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →
Regulatory Differences
This is the most significant distinction between the two options:
Brand-Name FDA Approval
Wegovy and Ozempic went through the full FDA approval process, including large-scale clinical trials (STEP and SUSTAIN programs). This means the specific formulation, manufacturing process, and delivery device have been reviewed and approved by the FDA.
Compounding Pharmacy Oversight
Compounded semaglutide is prepared under different regulatory frameworks:
- 503A pharmacies: Regulated by state boards of pharmacy. They prepare medications based on individual patient prescriptions and must follow USP compounding standards .
- 503B outsourcing facilities: Registered with the FDA and subject to FDA inspections. They can prepare medications in larger batches and must follow current Good Manufacturing Practice (cGMP) guidelines .
While compounded products aren't "FDA-approved" as finished products, the regulatory oversight ensures quality and safety when sourced from reputable pharmacies .
Cost Comparison
Cost is the driving factor for most patients who choose compounded semaglutide:
- Brand-name Wegovy: approximately $1,300 per month without insurance $1,300-$1,400/mo (brand)
- Brand-name Ozempic (off-label for weight loss): similar pricing $900-$1,000/mo (brand)
- Compounded semaglutide: typically a fraction of brand-name cost through platforms like FormBlends Contact provider for current pricing
Even patients with insurance coverage for brand-name products may face high copays, prior authorization requirements, or step therapy requirements that delay access. Cash-pay compounded options bypass these barriers entirely.
Delivery Method
Brand-name Wegovy comes in a pre-filled injection pen that's ready to use. Compounded semaglutide typically comes in a multi-dose vial with insulin syringes for self-injection. While the vial-and-syringe method requires slightly more preparation, most patients find it straightforward after initial guidance from their provider.
Which Should You Choose?
Choose brand-name if:
- Your insurance covers it with an affordable copay
- You prefer the convenience of a pre-filled pen
- You want a product that went through the full FDA approval process
Choose compounded if:
- Cost is a primary concern and you want an affordable option
- You don't have insurance coverage for Wegovy or Ozempic
- Brand-name products are experiencing supply shortages
- You're comfortable with vial-and-syringe administration
Discuss your options with a licensed provider through FormBlends to determine the best fit for your situation.
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
Frequently Asked Questions
Is compounded semaglutide safe?
When sourced from a licensed 503A or 503B pharmacy, compounded semaglutide is considered safe. The active ingredient is identical to the brand-name version. Quality depends on the pharmacy's adherence to compounding standards and sterility protocols is compounded semaglutide as effective.
Will I get the same results from compounded semaglutide?
Patients and providers widely report comparable appetite suppression and weight loss results with compounded semaglutide. Since the active ingredient is the same, the expected outcomes should be similar when the medication is properly dosed and prepared .
Can I switch from Wegovy to compounded semaglutide?
Yes. Many patients switch from brand-name to compounded semaglutide to reduce costs. Your provider can transition you at the same dose level without needing to restart the escalation process how to switch from Ozempic to compounded semaglutide.
Why is compounded semaglutide so much cheaper?
Brand-name drug pricing reflects the manufacturer's investment in clinical trials, FDA approval, marketing, and patent protections. Compounding pharmacies avoid most of these costs since they use the already-established active ingredient. This allows them to offer the medication at a lower price point cheapest way to get semaglutide.
Will compounded semaglutide always be available?
Compounded semaglutide availability is tied to FDA drug shortage designations and evolving regulations. As of early 2026, it remains available through licensed compounding pharmacies. Patients should stay informed through their provider about any regulatory changes .